Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 401–500 of 1,020
Fujikura, K., Hosoda, W., Felsenstein, M., Song, Q., Reiter, J. G., Zheng, L., Beleva Guthrie, V., Rincon, N., Dal Molin, M., Dudley, J., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321217 · Cited by 89
Self-citationGut Microbiota-Immune System Crosstalk and Pancreatic Disorders
Pagliari, D., Saviano, A., Newton, E. E., Serricchio, M. L., Dal Lago, A. A., Gasbarrini, A., & Cianci, R. (2018) · Mediators of Inflammation · doi:10.1155/2018/7946431 · Cited by 89
“About 95% of them are adenocarcinomas that originate from gland, ductal, or acinar cells of the exocrine pancreas [116].”
BackgroundGlassman, D. C., Palmaira, R. L. D., Covington, C. M., Desai, A. M., Ku, G. Y., Li, J., Harding, J. J., Varghese, A. M., O'Reilly, E. M., & Yu, K. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4605-1 · Cited by 92
Porcelli, L., Iacobazzi, R. M., Fonte, R., Serratì, S., Intini, A., Solimando, A. G., Brunetti, O., Calabrese, A., Leonetti, F., Azzariti, A., et al. (2019) · Cancers · doi:10.3390/cancers11030330 · Cited by 97
“This because, when deregulated, the TGF-β signalling [16] plays a crucial role in the paracrine crosstalk between epithelial tumor cells and stroma cells to promote tumor growth, extracellular matrix remodelling, stemness, evasion of immune surveillance and cancer drug resistance [17–21].”
BackgroundTranscriptional control of subtype switching ensures adaptation and growth of pancreatic cancer
Adams, C. R., Htwe, H. H., Marsh, T., Wang, A. L., Montoya, M. L., Subbaraj, L., Tward, A. D., Bardeesy, N., & Perera, R. M. (2019) · eLife · doi:10.7554/elife.45313 · Cited by 88
Burrack, A. L., Spartz, E. J., Raynor, J. F., Wang, I., Olson, M. A., & Stromnes, I. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.059 · Cited by 93
Large, T. Y. S. L., Bijlsma, M. F., Kazemier, G., van Laarhoven, H. W. M., Giovannetti, E., & Jiménez, C. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.008 · Cited by 97
Camolotto, S. A., Pattabiraman, S., Mosbruger, T. L., Jones, A. D., Belova, V. K., Orstad, G., Streiff, M., Salmond, L., Stubben, C., Kaestner, K. H., et al. (2018) · eLife · doi:10.7554/elife.38579 · Cited by 92
“For example, pancreatic ductal adenocarcinoma (PDAC) and its precursors often express many of the same foregut markers as NKX2-1-negative lung adenocarcinoma (Tata et al., 2018; Bailey et al., 2016; Prasad et al., 2005).”
BackgroundSquamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation
Somerville, T. D., Biffi, G., Daßler-Plenker, J., Hur, S. K., He, X.-Y., Vance, K. E., Miyabayashi, K., Xu, Y., Maia-Silva, D., Klingbeil, O., et al. (2020) · eLife · doi:10.7554/elife.53381 · Cited by 87
“The designation of adenosquamous pancreatic cancer as a disease entity has been reinforced by several recent transcriptome profiling studies of human pancreatic tumors, which identified aberrant expression of squamous (also known as basal) lineage markers in ~15% of samples, in association with exceptionally poor clin…”
BackgroundInfluentialMills, B. N., Connolly, K. A., Ye, J., Murphy, J. D., Uccello, T. P., Han, B. J., Zhao, T., Drage, M. G., Murthy, A., Qiu, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.095 · Cited by 91
“Poor survival statistics are the result of common dysfunctions in core signaling pathways, including cell growth (KRAS), DNA damage control (TP53), and cell cycle regulation (CDKN2A) (Bailey et al., 2016).”
BackgroundCellular determinants and therapeutic implications of inflammation in pancreatic cancer
Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 91
Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer
Liu, X., Liu, L., Ji, Y., Li, C., Wei, T., Yang, X., Zhang, Y., Cai, X., Yang, T., Gao, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.010 · Cited by 90
“First, we selected the 62most recurrentlymutated genes in common cancer types according to the TCGA, ICGC database [36] and large-scale cohorts relevant to pancreatic cancer sequencing [5,9,10,37].”
MethodPORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers
Zhong, Z., Sepramaniam, S., Chew, X. H., Wood, K., Lee, M. A., Madan, B., & Virshup, D. M. (2019) · Oncogene · doi:10.1038/s41388-019-0908-1 · Cited by 87
Yang, G., Guan, W., Cao, Z., Guo, W., Xiong, G., Zhao, F., Feng, M., Qiu, J., Liu, Y., Zhang, M. Q., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3975 · Cited by 91
“Many studies tried to subtype pancreatic cancer by large-scale genomic profiling to identify candidatemolecular mechanisms of drug resistance (17, 18).”
BackgroundNigri, J., Leca, J., Tubiana, S.-S., Finetti, P., Guillaumond, F., Martinez, S., Lac, S., Iovanna, J., Audebert, S., Camoin, L., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abg8191 · Cited by 97
Redox signaling in the pancreas in health and disease
Sastre, J., Pérez, S., Sabater-Orti, L., & Rius‐Pérez, S. (2024) · Physiological Reviews · doi:10.1152/physrev.00044.2023 · Cited by 111
Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative
van den Braak, R. R. J. C., van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbée, M., Henegouwen, M. I. V. B., Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R., et al. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1346381 · Cited by 95
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes
Zhao, L., Zhao, H., & Yan, H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4546-8 · Cited by 98
“To compare our classification system with three previously published results [18, 20, 23], we then used our PDAC classifier to classify these three cohorts, separately.”
Niu, N., Lu, P., Yang, Y., He, R., Zhang, L., Shi, J., Wu, J., Yang, M., Zhang, Z.-G., Wang, L.-W., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318362 · Cited by 86
Self-citationMutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
Taylor, J., & Lee, S. C.-W. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22784 · Cited by 108
Huang, W., Navarro-Serer, B., Jeong, Y. J., Chianchiano, P., Xia, L., Luchini, C., Veronese, N., Dowiak, C., Ng, T., Trujillo, M. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1523 · Cited by 85
“In multiple studies, PDACs with a mesenchymal gene expression phenotype also displayed a worse clinical outcome (8, 20, 21).”
BackgroundSelf-citationCao, L., Wu, J., Qu, X., Sheng, J., Cui, M., Liu, S., Huang, X., Xiang, Y., Li, B., Zhang, X., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01765-x · Cited by 98
Self-citationGautam, S. K., Batra, S. K., & Jain, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01813-y · Cited by 106
“Non-receptor tyrosine kinases such as HCK and Steroid receptor co-activator (SRC) kinase are also key mediators of innate immunity and have been reported to regulate immunosuppression in multiple cancers, including PDAC [67, 213, 226].”
BackgroundSWI/SNF component ARID1A restrains pancreatic neoplasia formation
Wang, S. C., Nassour, I., Xiao, S., Zhang, S., Luo, X., Lee, J., Li, L., Sun, X., Nguyen, L. H., Chuang, J.-C., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315490 · Cited by 85
Chakraborty, J., Langdon-Embry, L., Cunanan, K. M., Escalon, J. G., Allen, P. J., Lowery, M. A., O’Reilly, E. M., Gönen, M., Do, R. G., & Simpson, A. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188022 · Cited by 85
Wang, X., Wu, X., Zhang, Z., Ma, C., Wu, T., Tang, S., Zeng, Z., Huang, S., Gong, C., Yuan, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36214-5 · Cited by 94
Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer
Roa-Peña, L., Leiton, C. V., Babu, S., Pan, C.-H., Vanner, E. A., Akalin, A., Bandovic, J., Moffitt, R. A., Shroyer, K. R., & Escobar-Hoyos, L. F. (2019) · Scientific Reports · doi:10.1038/s41598-019-47519-4 · Cited by 85
Gupta, R., Malvi, P., Parajuli, K. R., Janoštiak, R., Bugide, S., Cai, G., Zhu, L. J., Green, M. R., & Wajapeyee, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005156117 · Cited by 96
“Currently, there is no effective therapy for PDAC, and a detailed molecular and functional evaluation of PDACs is needed to identify and develop better therapeutic strategies.”
BackgroundInfluentialFacts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 99
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 82
Self-citationLi, S., Li, K., Wang, K., Yu, H., Wang, X., Shi, M., Liang, Z., Zhou, Y., Hu, Y., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43462-1 · Cited by 98
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.009 · Cited by 84
“PDAC is associated with the highest frequency of KRAS mutations of any tumor type [16].”
BackgroundLiu, X., Xu, J., Zhang, B., Liu, J., Liang, C., Meng, Q., Hua, J., Yu, X., & Shi, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1117-9 · Cited by 83
Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology
Feldmann, K., Maurer, C., Peschke, K., Teller, S., Schuck, K., Steiger, K., Engleitner, T., Öllinger, R., Nomura, A., Wirges, N., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.010 · Cited by 84
Massihnia, D., Avan, A., Funel, N., Maftouh, M., van Krieken, A., Granchi, C., Raktoe, R. S., Boggi, U., Aicher, B., Minutolo, F., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0371-1 · Cited by 90
“Of note, recent genomic studies showed that the PI3K/ Akt signaling is among the core signaling pathways leading the intrinsic aggressiveness of PDAC, suggesting that in the PDAC actionable genome about 9 and 6% of the cases are Akt- and PI3K-dependent, respectively [50].”
BackgroundMurakami, S., Nemazanyy, I., White, S. M., Chen, H., Nguyen, C. D. K., Graham, G. T., Saur, D., Pende, M., & Yi, C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.07.022 · Cited by 83
“Over 70% of human PDACs contain TP53 mutations, which promote PDAC progression into a more aggressive and poorly differentiated basal-like/squamous subtype (Bailey et al., 2016; Hingorani et al., 2005; Vanderas and Papagiannoulis, 2002).”
BackgroundA pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
Duan, X., Zhang, T., Feng, L., de Silva, N., Greenspun, B. C., Wang, X., Moyer, J. E., Martin, M. L., Chandwani, R., Elemento, O., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.011 · Cited by 89
McIntyre, C. A., Grimont, A., Park, J., Meng, Y., Sisso, W. J., Seier, K. P., Jang, G. H., Walch, H. S., Aveson, V. G., Falvo, D. J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.002 · Cited by 97
Concepts to Target MYC in Pancreatic Cancer
Wirth, M., Mahboobi, S., Krämer, O. H., & Schneider, G. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0050 · Cited by 85
“The squamous subtype of the disease, which overlaps with the quasi-mesenchymal subtype defined by Collisson and colleagues (21), is characterized by an activated MYC pathway (20) and the poorest outcome (20-22).”
BackgroundPancreatic cancer survival analysis defines a signature that predicts outcome
Raman, P., Maddipati, R., Lim, K., & Tözeren, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201751 · Cited by 96
Sugimori, M., Sugimori, K., Tsuchiya, H., Suzuki, Y., Tsuyuki, S., Kaneta, Y., Hirotani, A., Sanga, K., Tozuka, Y., Komiyama, S., et al. (2019) · Cancer Science · doi:10.1111/cas.14245 · Cited by 87
Knudsen, E. S., Kumarasamy, V., Chung, S., Ruiz, A., Vail, P., Tzetzo, S., Wu, J., Nambiar, R., Sivinski, J., Chauhan, S. S., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321000 · Cited by 82
Self-citationWang, C., Zhang, T., Liao, Q., Dai, M., Guo, J., Yang, X., Tan, W., Lin, D., Wu, C., & Zhao, Y. (2021) · Protein & Cell · doi:10.1007/s13238-020-00760-4 · Cited by 82
Modeling pancreatic cancer in mice for experimental therapeutics
Mallya, K. B., Gautam, S. K., Aithal, A., Batra, S. K., & Jain, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188554 · Cited by 98
Siolas, D., Vucic, E., Kurz, E., Hajdu, C., & Bar-Sagi, D. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109578 · Cited by 80
“In particular, the squamous subtype is correlated with TP53 mutations and has been observed to be enriched for a distinct immune cell-specific gene expression signature (Bailey et al., 2016).”
BackgroundHigh immune cell score predicts improved survival in pancreatic cancer
Tahkola, K., Mecklin, J., Wirta, E., Ahtiainen, M., Helminen, O., Böhm, J., & Kellokumpu, I. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2297-1 · Cited by 90
“Subtypes defined by different mutational background are associated with distinct histopathological characteristics and survival [5, 6].”
BackgroundDijk, F., Veenstra, V. L., Soer, E. C., Dings, M. P. G., Zhao, L., Halfwerk, J. B. G., Hooijer, G. K. J., Damhofer, H., Marzano, M., Steins, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56826-9 · Cited by 94
Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion
Murray, E. R., Menezes, S., Henry, J. C., Williams, J. L., Alba‐Castellón, L., Baskaran, P., Quétier, I., Desai, A., Marshall, J. J. T., Rosewell, I. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110227 · Cited by 99
Hirt, C., Booij, T. H., Grob, L., Simmler, P., Toussaint, N. C., Keller, D., Taube, D., Ludwig, V., Goryachkin, A., Pauli, C., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100095 · Cited by 109
FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer
Canel, M., Sławińska, A., Lonergan, D. W., Kallor, A. A., Upstill‐Goddard, R., Davidson, C., von Kriegsheim, A., Biankin, A. V., Byron, A., Alfaro, J. A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327927 · Cited by 95
Self-citationImmune checkpoint therapy for pancreatic cancer
Johansson, H., Andersson, R. E., Bauden, M. P., Hammes, S., Holdenrieder, S., & Ansari, D. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i43.9457 · Cited by 91
Jiang, N., Qiao, G., Wang, X., Morse, M. A., Gwin, W. R., Zhou, L., Song, Y., Zhao, Y., Chen, F., Zhou, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0492 · Cited by 79
“Bailey and colleagues reported an immunogenic subtype of APC through genomic analyses to select patients who might respond to immunotherapy (32).”
BackgroundSuenaga, M., Yu, J., Shindo, K., Tamura, K., Almario, J. A., Zaykoski, C., Witmer, P. D., Fesharakizadeh, S., Borges, M., Lennon, A.-M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2463 · Cited by 81
“As the most important goal of pancreatic surveillance is to detect evidence of pancreatic cancer or high-grade dysplasia, patients were grouped into those with pancreatic cancer or high-grade dysplasia (PanIN-3 or in IPMN) versus all others (disease controls, those under surveillance, and those with low-grade dysplasi…”
BackgroundInfluentialLysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming
Κουτσιούμπα, Μ., Hatziapostolou, M., Polytarchou, C., Tolosa, E. J., Almada, L. L., Mahurkar‐Joshi, S., Williams, J. L., Tirado-Rodriguez, A. B., Huerta‐Yépez, S., Karavias, D. D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315690 · Cited by 95
Schaefer, D., Tomiuk, S., Kuester, L. N., Rawashdeh, W. A., Henze, J., Tischler-Höhle, G., Agorku, D., Brauner, J., Linnartz, C., Lock, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21774-4 · Cited by 88
Alonso‐Nocelo, M., Ruíz-Cañas, L., Sancho, P., Görgülü, K., Alcalá, S., Pedrero, C., Vallespinós, M., López-Gil, J. C., Ochando, M., García-García, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325564 · Cited by 98
“36 Gene Set Enrichment Analysis (GSEA) comparing the samples belonging to the top and bottom quartiles of LOXL2 expression for the three aforementioned data sets was performed, and we observed significantly and commonly enriched pathways across all series (online supplemental figure S2A), with…”
Li, Y., Tang, S., Shi, X., Lv, J., Wu, X., Zhang, Y., Wang, H., He, J., Zhu, Y., Ju, Y., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101162 · Cited by 104
“In the absence of appropriate longitudinal data, the Bailey PDAC cohort (n = 55 patients) and the TCGA PDAC cohort (n = 156 patients) were classified into two subtypes based on the expression of metabolic signature genes.(8,33) Patients with glucomet-PDAC showed significantly worse overall survival than patients with…”
MethodDigestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 100
Lost in translation: returning germline genetic results in genome-scale cancer research
Initiative, A. P. C. G., Johns, A. L., McKay, S. H., Humphris, J. L., Pinese, M., Chantrill, L. A., Mead, R. S., Tucker, K., Andrews, L., Goodwin, A., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0430-4 · Cited by 79
“We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal DNA pairs from eligible patients to an average depth of 65× (tumour) and 35× (germline) under conditions previously described by this group [1, 32, 33].”
MethodSelf-citationOrganoid models for translational pancreatic cancer research
Tiriac, H., Plenker, D., Baker, L. A., & Tuveson, D. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.003 · Cited by 79
Argentiero, A., Summa, S. D., Fonte, R., Iacobazzi, R. M., Porcelli, L., Vià, M. D., Brunetti, O., Azzariti, A., Silvestris, N., & Solimando, A. G. (2019) · Cancers · doi:10.3390/cancers11070942 · Cited by 80
Yap, T. A., Vieito, M., Baldini, C., Sepúlveda-Sánchez, J. M., Kondo, S., Simonelli, M., Cosman, R., van der Westhuizen, A., Atkinson, V. G., Carpentier, A. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1504 · Cited by 86
“Among several tumor types, TGFb has a particularly relevant role in pancreatic cancer with the signal transduction pathway commonly mutated in this disease, as confirmed in recent whole-genome or exome sequencing analyses (15).”
BackgroundCancer‐associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets
Menezes, S., Okail, M. H., Jalil, S. M. A., Kocher, H. M., & Cameron, A. J. M. (2022) · The Journal of Pathology · doi:10.1002/path.5926 · Cited by 91
Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth
Rath, N., Munro, J., Cutiongco, M. F., Jagiełło, A., Gadegaard, N., McGarry, L., Unbekandt, M., Michalopoulou, E., Kamphorst, J. J., Sumpton, D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1339 · Cited by 77
“One challenge for chemotherapy is that the mostly commonly mutated driver genes (KRAS, TP53, SMAD4 and CDKN2A (4,5)) are not targeted by current drugs.”
Self-citationPoudel, P., Nyamundanda, G., Patil, Y., Cheang, M. C. U., & Sadanandam, A. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0116-8 · Cited by 91
ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer
Huang, Y.-H., Hu, J., Chen, F., Lecomte, N., Basnet, H., David, C. J., Witkin, M. D., Allen, P. J., Leach, S. D., Hollmann, T. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0529 · Cited by 78
“© 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from Figure 1 Positive Negative 0 20 40 60 80 100 SMAD4 N um be r o f C as es Human PDA pSMAD2/3: Positive Negative -2 DA MSp +2 DA MSp BA AHR KLF5 HMGB2 ID1 PPARG MLXIPL NFIC NR5A2 BHLHA15 RBPJL PDA Normal 875 1Rank F D PDA PNET Normal…”
MethodSelf-citationGastric Cancer Genomics: Advances and Future Directions
Katona, B. W., & Rustgi, A. K. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.003 · Cited by 78
“Genomic data have been used to develop molecular classification systems for many types of cancer including colorectal cancer(19) and pancreatic cancer.(20) Although classic classification criteria for gastric cancer has been histologically based (eg, Lauren’s(3) and World Health Organization),(4) recent use of genomic…”
MethodSplice variants as novel targets in pancreatic ductal adenocarcinoma
Wang, J., Dumartin, L., Mafficini, A., Ulug, P., Sangaralingam, A., Alamiry, N. A., Radon, T. P., Salvia, R., Lawlor, R. T., Lemoine, N. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03354-z · Cited by 81
Self-citationMartens, S., Lefesvre, P., Nicolle, R., Biankin, A. V., Puleo, F., Laethem, J. V., & Rooman, I. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz181 · Cited by 88
“The differentiation grade also differed (Table 2): basal-like tumours were more often poorly differentiated, while classical tumours were more often well differentiated [18–23, 25, 26].”
InfluentialSelf-citationClinical Impact of Molecular Subtyping of Pancreatic Cancer
Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 87
“The Squamous subtype overlaps with the Quasi-mesenchymal subtype of Collisson but has notable pan-squamous features, including a significant association with adenosquamous PDAC histology (Bailey et al., 2016).”
BackgroundMethodInfluentialSelf-citationCo-clinical Assessment of Tumor Cellularity in Pancreatic Cancer
Heid, I., Steiger, K., Trajkovic‐Arsic, M., Settles, M., Eßwein, M. R., Erkan, M., Kleeff, J. H., Jäger, C., Friess, H., Haller, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2432 · Cited by 96
Pishvaian, M. J., Biankin, A. V., Bailey, P. J., Chang, D. K.-F., Laheru, D. A., Wolfgang, C. L., & Brody, J. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.40 · Cited by 85
Self-citationHNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer
Kalisz, M., Bernardo, E., Beucher, A., Maestro, M. A., del Pozo, N., Millán, I., Haeberle, L., Schlensog, M., Safi, S. A., Knoefel, W. T., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102808 · Cited by 77
“Samples from the ICGC-PACA-AU study were classified into molecular subtypes based on signature genes from Collisson et al (2011), Moffitt et al (2015), or Bailey et al (2016).”
BackgroundMethodInfluentialPatil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0672 · Cited by 90
“Molecularly, PDAC is characterized by signature mutations in KRAS, TP53, CDKN2A, and SMAD4 that regularly co-occur with a set of additionally altered genes (3).”
BackgroundResultInfluentialYang, J., Lin, P., Yang, M., Liu, W. C., Fu, X., Liu, D., Tao, L., Huo, Y., Zhang, J., Hua, R., et al. (2021) · Genome biology · doi:10.1186/s13059-020-02222-w · Cited by 80
“Transcriptomic characteristics of PDAC primary tumors have also been systematically studied [7, 9, 13].”
BackgroundResultInfluentialDruggable genome and precision medicine in cancer: current challenges
Dupont, C., Riegel, K., Pompaiah, M., Juhl, H. H., & Rajalingam, K. (2021) · FEBS Journal · doi:10.1111/febs.15788 · Cited by 86
Nel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 84
Masugi, Y. (2022) · Cancers · doi:10.3390/cancers14133293 · Cited by 102
Saillard, C., Delecourt, F., Schmauch, B., Moindrot, O., Svrcek, M., Bardier–Dupas, A., Emile, J., Ayadi, M., Rebours, V., de Mestier, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39026-y · Cited by 89
Chiaro, P. D., Nacci, L., Arco, F., Brandini, S., Polletti, S., Palamidessi, A., Donati, B., Soriani, C., Gualdrini, F., Frigè, G., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.017 · Cited by 88
Yarchoan, M., Myzak, M. C., Johnson, B. A., De Jesus-Acosta, A., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 77
“Somatic mutations affecting genes involved in homologous DNA repair are also identified in a small percentage of pancreatic cancers [18].”
BackgroundSeo, J., Kim, A., Shin, J.-Y., & Kim, Y. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-32855-8 · Cited by 79
McIntyre, C. A., Lawrence, S. A., Richards, A. L., Chou, J. F., Wong, W., Capanu, M., Berger, M. F., Donoghue, M. T. A., Yu, K. H., Varghese, A. M., et al. (2020) · Cancer · doi:10.1002/cncr.33038 · Cited by 76
Self-citationLi, J., Lama, R., Galster, S. L., Inigo, J. R., Wu, J., Chandra, D., Chemler, S. R., & Wang, X. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0728 · Cited by 87
Self-citationMYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 100
Bhagwat, N., Dulmage, K., Pletcher, C. H., Wang, L., DeMuth, W., Sen, M., Balli, D., Yee, S. S., Sa, S., Tong, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23217-5 · Cited by 75
YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma
Tu, B., Yao, J., Ferri-Borgogno, S., Zhao, J., Chen, S., Wang, Q., Yan, L., Zhou, X., Zhu, C., Bang, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130811 · Cited by 75
Self-citationTMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis
Crottès, D., Lin, Y.-H. T., Peters, C. J., Gilchrist, J. M., Wiita, A. P., Jan, Y. N., & Jan, L. Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1900703116 · Cited by 82
Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
Pereira, M. A., & Chio, I. I. C. (2019) · Genes · doi:10.3390/genes11010006 · Cited by 95
Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment
Pan, X., & Zheng, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0505-9 · Cited by 75
“The use of DNMTi decitabine only partially reversed this M1–M2 transition of macrophages in PDA.”
BackgroundInfluentialGiuliani, V., Miller, M. A., Liu, C.-Y., Hartono, S. R., Class, C. A., Bristow, C. A., Suzuki, É., Sanz, L. A., Gao, G., Gay, J. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24798-y · Cited by 81
Self-citationKim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01287-7 · Cited by 90
Vernerey, D., Huguet, F., Vienot, A., Goldstein, D., Paget‐Bailly, S., Laethem, J. V., Glimelius, B. L. G., Artru, P., Moore, M. J., André, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.212 · Cited by 75
Noncoding Rnas as Novel Biomarkers in Pancreatic Cancer: what do we Know?
Previdi, M. C., Carotenuto, P., Zito, D., Pandolfo, R., & Braconi, C. (2016) · Future Oncology · doi:10.2217/fon-2016-0253 · Cited by 80
ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Armstrong, S. A., Schultz, C. W., Azimi-Sadjadi, A., Brody, J. R., & Pishvaian, M. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0208 · Cited by 73
“Multiple studies have reaffirmed the importance of TP53, KRAS, CDKN2A, and SMAD4mutations in PDAC (7, 11, 43, 44).”
BackgroundTherapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 82
“A conspicuous TGF-β -associated transcriptional signature can discriminate specific molecular subtypes in several cancers [118–120]; in colorectal cancers, transcriptomic profiling revealed four consensus molecular subtypes (CMS), where CMS4 is characterized by prominent mesenchymal features that…”
D’Errico, G., Alonso‐Nocelo, M., Vallespinós, M., Hermann, P. C., Alcalá, S., Pedrero, C., Martín-Hijano, L., Valle, S., Earl, J., Cassiano, C., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0803-9 · Cited by 83
Opportunities and Challenges for Pancreatic Circulating Tumor Cells
Nagrath, S., Jack, R. M., Sahai, V., & Simeone, D. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.052 · Cited by 75
Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on
Verbeke, C. S., Häberle, L., Lenggenhager, D. M., & Esposito, I. (2018) · Pancreatology · doi:10.1016/j.pan.2018.04.010 · Cited by 76
HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties
Abel, E. V., Goto, M., Magnuson, B., Abraham, S. T., Ramanathan, N., Hotaling, E., Alaniz, A. A., Kumar‐Sinha, C., Dziubinski, M. L., Urs, S., et al. (2018) · eLife · doi:10.7554/elife.33947 · Cited by 83
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.